Day: March 6, 2023

Target estimated savings in the range of $65-$75 million for 2023 Process automation, Work from Anywhere and Anytime solutions lead realignmentIRVING, Texas, March 06, 2023 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ: XELA, XELAP), a global business process automation leader, today announced updates to its 2023 operational performance improvement objectives. During the fourth quarter, the Company announced operational performance improvement targets by focusing on automation led efficiencies. The company has identified additional savings to help restore historically higher margins relative to recent financial reporting periods and plans to right-size the organization in the face of continuing tight job markets and higher employee costs. “Automation initiatives are leading to process improvements...

INFORMATION CONCERNING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES Declaration pursuant to Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des marchés financiers (AMF)Date of settlementof information Total number of shares Number of shares without voting rights (*) Number of voting rights for threshold calculation (**) Number of actual voting rights (exercisable at shareholders’ meeting)February 28, 2023 20 455 403 319 981 22 818 769 22 498 788January 31, 2023 20 455 403 253 414 22 892 958 22 639 544December 31, 2022 20 455 403 250 392 22 948 713 22 698 321(*) exclusively consisting of treasury shares.(**) theoretical voting rights to calculate the threshold crossing including the voting right of treasury shares (article 223-11 of the General Regulations AMF). About...

WATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company’s chief executive officer and president, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Monday, March 13, 2023 at 3:20 p.m. ET at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually. To access the live webcast of this presentation, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations....

US Hospital Claims Data Reveals Cardiogenic Shock Patients Have an Average Hospital Length of Stay of 19.6 Days Making Its Intensive Patient Care Cost Very High WARRINGTON, Pa., March 06, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, is targeting cardiogenic shock as a potential indication for its drug candidate, istaroxime and today announces results of a recently completed market study.    Innovative therapeutic interventions have the potential to decrease the long length of hospital stay associated with cardiogenic shock and its resulting high cost to the health care system. US hospital claims data obtained by Windtree show that in 2020 the US average cardiogenic shock patient...